US Tariffs on Indian pharma ultimately burdening American consumers: Pharmexcil

Hyderabad, Aug. 8 -- US tariff on Indian Pharma would be counterproductive, ultimately burdening American consumers, according to Pharmexcil.

In a statement today, Pharmexcil Chairman Namit Joshi said "The US decision to temporarily exempt Indian pharmaceutical exports from increased tariffs, subject to the outcome of the investigation under Section 232 of the Trade Expansion Act of 1962, reiterates India's critical role in ensuring affordable, high-quality medicines for the American population.

India supplies over 40 percent of generics used in the US, including treatments for chronic diseases, cancer, and infectious conditions, he said.

Tariffs on Indian pharma would be counterproductive, ultimately burdening American consumers, he sai...